Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Shares Outstanding (Weighted Average) (2016 - 2025)

KalVista Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 11 years, with the latest figure at $49.7 million for Q2 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 34.98% to $49.7 million in Q2 2025 year-over-year; TTM through Apr 2025 was $49.7 million, a 34.98% increase, with the full-year FY2025 number at $49.7 million, up 34.98% from a year prior.
  • Shares Outstanding (Weighted Average) hit $49.7 million in Q2 2025 for KalVista Pharmaceuticals, roughly flat from $49.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for KALV hit a ceiling of $49.7 million in Q2 2025 and a floor of $18.0 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $36.1 million across 4 years, with a median of $34.7 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 0.69% in 2021 and later soared 34.98% in 2025.
  • Tracing KALV's Shares Outstanding (Weighted Average) over 4 years: stood at $19.1 million in 2021, then soared by 81.03% to $34.6 million in 2023, then surged by 43.01% to $49.4 million in 2024, then rose by 0.44% to $49.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for KALV at $49.7 million in Q2 2025, $49.4 million in Q4 2024, and $46.5 million in Q4 2024.